Oncology PracticeMany actionable mutations may be missed in current testing of advanced RCCJuly 9, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeKEYNOTE-427: Pembrolizumab monotherapy shows promise in accRCCJune 25, 2018Renal Cell CarcinomaGenitourinary CancerImmuno-oncology
Oncology PracticeProtein activation could predict renal cell carcinoma recurrenceJune 14, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeIMDC model mirrors mRCC clinical outcomesMay 21, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeIs cancer immunotherapy more effective in men than women?May 16, 2018Immuno-oncologyImmunotherapyGenitourinary CancerGastroenterologyRenal Cell CarcinomaMelanomaLung Cancer
Oncology PracticeCheckpoint inhibitors get to patients quicklyMay 10, 2018Renal Cell CarcinomaImmuno-oncologyLung CancerMelanoma
Oncology PracticeAlternate 2:1 sunitinib schedule showed safety gains in renal cell carcinomaApril 26, 2018Renal Cell Carcinoma
Oncology PracticeCompany discontinues phase 3 ADAPT for mRCCApril 23, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeFDA approves immunotherapy combo for advanced RCCApril 17, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeDo industry payments increase prescribing for some targeted therapies?April 9, 2018Practice ManagementRenal Cell CarcinomaLeukemia, Myelodysplasia, TransplantationCMLBusiness of Medicine
Oncology PracticeDiabetes from checkpoint inhibitors probably means lifelong insulinApril 8, 2018MelanomaRenal Cell CarcinomaGenitourinary Cancer
Oncology PracticeTivozanib after sorafenib promising in patients with advanced RCCApril 7, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeAxitinib/avelumab combo shows preliminary efficacy in RCCMarch 17, 2018Renal Cell Carcinoma
Oncology PracticeExcellent prognosis for cystic RCC evaluated with radiologic threshold of greater than 50%March 7, 2018Renal Cell CarcinomaGenitourinary Cancer
Oncology PracticeImmunotherapy regimen influences inflammatory arthritis presentationMarch 5, 2018Patient & Survivor CareImmuno-oncologyAggressive LymphomasRenal Cell CarcinomaMelanoma
